Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ
Stephanie Graff, Director of Breast Oncology at Brown University Health and an Associate Professor of Medicine at Brown University’s Legorreta Cancer Center, shared on X:
“Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial | Breast Cancer | JAMA | JAMA Network.”
Authors: E. Shelley Hwang, Terry Hyslop, Thomas Lynch, Marc D. Ryser, Anna Weiss, Anna Wolf, Kelsey Norris, Meredith Witten, Lars Grimm, Stuart Schnitt, Sunil Badve, Rachel Factor, Elizabeth Frank, Deborah Collyar, Desiree Basila, Donna Pinto, Mark A. Watson, Robert West, Louise Davies, Jenny L. Donovan, Ayako Shimada, Yutong Li, Yan Li, Antonia V. Bennett, Shoshana Rosenberg, Jeffrey Marks, Eric Winer, Marc Boisvert, Armando Giuliano, Kelsey E. Larson, Kathleen Yost, Priscilla F. McAuliffe, Amy Krie, Nina Tamirisa, Lisa A. Carey, Alastair M. Thompson, Ann H. Partridge
Stephanie Graff is the Director of Breast Oncology at Brown University Health and an Associate Professor of Medicine at Brown University’s Legorreta Cancer Center.
She also serves as the Director of Breast Oncology at Lifespan and is a Medical Advisor for the Dr. Susan Love Foundation for Breast Cancer Research.She is an Associate Editor of Cancer Medicine, and chairs the editorial board of Oncology Times.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023